5-(2-amino-4-thiazolyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(2-amino-4-thiazolyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile
• 英文别名: 5-(2-amino-1,3-thiazol-4-yl)-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
• 化学式: C₁₀H₈N₄OS
• 分子量: 232.266
• InChiKey: AFCNJDCTKXZYMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氰乙酰胺 生成 5-(2-amino-4-thiazolyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile
  参考文献：
  名称：

  LESHER, G. Y.;SINGH, BALDEV

  摘要：

  DOI：

文献信息

• 5-(4-Thiazolyl)-6-alkyl-2(1H)-pyridinones and their cardiotonic use
  申请人：Sterling Drug Inc.

  公开号：US04469699A1

  公开（公告）日：1984-09-04

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-噻唑基)-6-R.sub.1 -2(1H)-吡啶酮(I)，其中R.sub.1是具有一至四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一至三个碳原子的烷基，Q是氨基，氨基甲酰基，羧基，氰基或氢，而Q'是具有一至四个碳原子的烷基，氨基或R.sub.4 NH，其中R.sub.4是具有一至四个碳原子的烷基，或它们的酸加成盐，其中至少有一个Q和Q'为氨基或Q'为R.sub.4 NH，可用作心脏强心剂（其中Q为氨基，氰基或氢）和/或中间体（其中Q为氰基，氨基甲酰基或羧基）。还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶基腈(II)作为中间体，以及制备I和II的方法。
• 5-(2-Substituted-4-thiazolyl)-6-alkyl-2(1H)-pyridinones and cardiotonic
  申请人：Sterling Drug Inc.

  公开号：US04539327A1

  公开（公告）日：1985-09-03

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-噻唑基)-6-R.sub.1 -2(1H)-吡啶酮(I)，其中R.sub.1是具有一到四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一到三个碳原子的烷基，Q是氨基，氨基甲酰基，羧基，氰基或氢，而Q'是具有一到四个碳原子的烷基，氨基或R.sub.4 NH，其中R.sub.4是具有一到四个碳原子的烷基，或其酸加成盐，其中至少一个Q和Q'是氨基或Q'是R.sub.4 NH，可用作心力衰竭药物(I，其中Q为氨基，氰基或氢)，和/或中间体(I，其中Q为氰基，氨基甲酰基或羧基)。还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶碳腈(II)作为中间体，以及制备I和II的过程。
• 5-.alpha.-bromoalkanoyl-2-oxo-3-pyridinecarbonitriles
  申请人：Sterling Drug Inc.

  公开号：US04595762A1

  公开（公告）日：1986-06-17

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-thiazolyl)-6-R.sub.1 -2(1H)-pyridinones (I), where R.sub.1 is alkyl having from one to four carbon atoms, R.sub.2 is hydrogen or methyl, R.sub.3 is hydrogen or alkyl having from one to three carbon atoms, Q is amino, carbamyl, carboxy, cyano or hydrogen, and Q' is alkyl having from one to four carbon atoms, amino or R.sub.4 NH where R.sub.4 is alkyl having from one to four carbon atoms, or acid-addition salts thereof where at least one of Q and Q' is amino or Q' is R.sub.4 NH, are useful as cardiotonics (I where Q is amino, cyano or hydrogen) and/or as intermediates (I where Q is cyano, carbamyl or carboxy). Also shown as intermediates are 1,2-dihydro-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-oxo-3-pyridinecarbonitriles (II), and, also, processes for preparing I and II.

  3-Q-4-R.sub.2 -5-(2-Q'-5-R.sub.3 -4-噻唑基)-6-R.sub.1 -2(1H)-吡啶酮(I)，其中R.sub.1是具有一到四个碳原子的烷基，R.sub.2是氢或甲基，R.sub.3是氢或具有一到三个碳原子的烷基，Q是氨基，氨基甲酰基，羧基，氰基或氢，Q'是具有一到四个碳原子的烷基，氨基或R.sub.4 NH，其中R.sub.4是具有一到四个碳原子的烷基，或其酸加成盐，其中至少有一个Q和Q'是氨基或Q'是R.sub.4 NH，可用作心脏强心剂（当Q为氨基，氰基或氢时的I）和/或中间体（当Q为氰基，氨基甲酰基或羧基时的I）。还显示了1,2-二氢-4-R.sub.2 -5-[R.sub.3 CH(Br)CO]-6-R.sub.1 -2-氧代-3-吡啶基腈（II）作为中间体，并且还提供了制备I和II的方法。
• Pyridone
  申请人：MERCK PATENT GmbH

  公开号：EP0154190A1

  公开（公告）日：1985-09-11

  Neue 2(1H)-Pyridone der allgemeinen Formel I worin R' sowie R3 bis R6 die in Patentanspruch 1 angegebene Bedeutung haben, sowie die entsprechenden Lactimester und Salze zeigen positiv inotrope Wirkungen.

  通式 I 的新 2(1H)-吡啶酮类化合物 其中 R'和 R3 至 R6 具有权利要求 1 所述的含义，相应的内酯和盐具有正性肌力作用。
• FUKASU, MIROCHI;KATO, YOSHIAKI;MURASE, SATOSHI;NAKAGAWA, SUSUMU, HETEROCYCLES, 29,(1989) N, C. 1517-1528
  作者：FUKASU, MIROCHI、KATO, YOSHIAKI、MURASE, SATOSHI、NAKAGAWA, SUSUMU

  DOI：——

  日期：——